The Rise of Precision BioSciences
The surge in Precision BioSciences (DTIL) shares by 20.4% to close at $16 on the last trading day was no random event. In truth, it was a force fueled by substantial trading volume and a flurry of investors who believe in the company’s lead gene editing program, PBGENE-HBV. This surge isn’t an isolated incident but part of a larger 22.4% gain over the past four weeks, indicating a path of upward momentum.
The investor excitement comes in the wake of Precision Biosciences receiving crucial feedback from regulatory authorities, including the FDA. The feedback affirmed alignment and clarity on the final new drug-enabling preclinical plans and clinical strategy for PBGENE-HBV, prepping it for an eventual move to phase I clinical studies. With plans to file an investigational new drug application for PBGENE-HBV in 2024 for chronic hepatitis B, the company is poised for a potentially groundbreaking move in the biotech industry.
Anticipating Growth
Analysts are eyeing Precision BioSciences with optimism, projecting quarterly earnings of $3 per share for the upcoming report, signaling a remarkable year-over-year change of +138.4%. In tandem, revenues are expected to skyrocket to $28.5 million, marking a significant 168.9% increase from the year-ago quarter.
A stock’s potential strength isn’t merely gauged by earnings and revenue numbers but also by shifts in earnings estimate revisions. With a stationary consensus EPS estimate for Precision BioSciences over the last 30 days, the trajectory remains consistent. Investors keen on DTIL must stay vigilant for any signs of shifting estimates that could propel the stock further along its upward trajectory.
Currently holding a Zacks Rank #3 (Hold), Precision BioSciences stands at a pivotal moment, one that could define its future performance in the market.
Industry Insights
Precision BioSciences operates within the Zacks Medical – Biomedical and Genetics industry, alongside players like Cue Biopharma, Inc. (CUE). While Precision BioSciences saw substantial gains, Cue Biopharma recorded a 5.5% increase in its stock price, closing at $2.12 during the last trading session. However, CUE has experienced a 23.9% dip in the past month, reflecting the volatile nature of the industry.
With Cue Biopharma, Inc. holding a consensus EPS estimate of -$0.29 for the upcoming report, expectations have remained steady over the last month. Despite the year-over-year EPS growth of +21.6%, Cue Biopharma, Inc. currently holds a Zacks Rank of #3 (Hold), highlighting a period of stability and uncertainty in the biopharma landscape.
Bright Prospects Ahead
A Look to the Future: Zacks Top 10 Stocks for 2024
Do you want to participate in the success stories of tomorrow? Zacks Top 10 Stocks for 2024 is a collection curated by Zacks Director of Research, Sheraz Mian. Since its inception in 2012 until November 2023, this exclusive portfolio has shown exceptional growth, surpassing the S&P 500’s performance. With a meticulously selected group of companies with immense growth potential, this opportunity is not to be missed. Join the early investors and uncover the next big hits before anyone else.
Unlock New Top 10 Stocks >>
Looking for reliable investment advice from Zacks Investment Research? Access the 7 Best Stocks for the Next 30 Days today. Click here to get your free report.
Precision BioSciences, Inc. (DTIL) : Free Stock Analysis Report
Cue Biopharma, Inc. (CUE) : Free Stock Analysis Report
For the original article on Zacks.com, click here.
Zacks Investment Research
The opinions expressed herein are solely those of the author and not necessarily those of Nasdaq, Inc.
